<DOC>
	<DOCNO>NCT00017199</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness PS-341 treating patient metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>PS-341 Treating Patients With Metastatic Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient metastatic neuroendocrine tumor treat bortezomib . - Determine toxicity drug patient population . - Determine pharmacodynamics correlate proteasome inhibition efficacy drug patient population . OUTLINE : This multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 21 day least 8 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . PROJECTED ACCRUAL : A total 16-25 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic carcinoid tumor islet cell tumor Welldifferentiated neuroendocrine tumor OR Welldifferentiated neuroendocrine carcinoma Measurable disease least 1 dimension At least 20 mm conventional technique OR least 10 mm spiral CT scan The following consider nonmeasurable : Lesions previously irradiate area Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed Cystic lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Leukocyte count least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study No history allergic reaction compound similar chemical biologic composition bortezomib Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy ( interferon alfa ) Chemotherapy : No 1 prior systemic chemotherapy regimen ( except hepatic artery chemoembolization ) At least 4 week since prior systemic chemotherapy ( 6 week nitrosoureas ) At least 12 week since prior hepatic artery chemoembolization ( unless liver lesion indicator lesion ) Stable dose longacting octreotide therapy ( Sandostatin LAR ) within past 3 month allow Concurrent subcutaneous octreotide breakthrough symptomatic relief allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent investigational agent , commercial agent , therapies No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>glucagonoma</keyword>
</DOC>